These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Efficacy and Prognostic Factors of Estracyt ® in Patients with Castration-Resistant Prostate Cancer (CRPC) : From the Data Analysis of Estracyt ® Special Drug Use Investigation]. Murachi K; Kumagai T; Masuda T; Nakanishi T; Tanaka S; Tajima K; Takebe Y; Oda T Hinyokika Kiyo; 2016 Jun; 62(6):295-306. PubMed ID: 27452492 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of estramustine phosphate sodium hydrate (EMP) monotherapy in castration-resistant prostate cancer patients: report of 102 cases and review of literature. Matsumoto K; Tanaka N; Hayakawa N; Ezaki T; Suzuki K; Maeda T; Ninomiya A; Nakamura S Med Oncol; 2013 Dec; 30(4):717. PubMed ID: 24005812 [TBL] [Abstract][Full Text] [Related]
6. Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience. Nakano K; Ohta S; Komatsu K; Kubo T; Nukui A; Suzuki K; Kurokawa S; Kobayashi M; Morita T BMC Urol; 2012 Feb; 12():3. PubMed ID: 22353627 [TBL] [Abstract][Full Text] [Related]
7. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy. Hirano D; Minei S; Kishimoto Y; Yamaguchi K; Hachiya T; Yoshida T; Yoshikawa T; Endoh M; Yamanaka Y; Yamamoto T; Satoh Y; Ishida H; Okada K; Takimoto Y Urol Int; 2005; 75(1):43-9. PubMed ID: 16037707 [TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer. Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348 [TBL] [Abstract][Full Text] [Related]
9. Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy. Du J; Yang Q; Chen XS; Tian J; Yao X Cancer Chemother Pharmacol; 2013 Nov; 72(5):1055-61. PubMed ID: 24043138 [TBL] [Abstract][Full Text] [Related]
10. Weekly low-dose docetaxel combined with estramustine and dexamethasone for Japanese patients with metastatic castration-resistant prostate cancer. Hatano K; Nishimura K; Nakai Y; Yoshida T; Sato M; Kawashima A; Mukai M; Nagahara A; Uemura M; Oka D; Nakayama M; Takayama H; Shimizu K; Meguro N; Tanigawa T; Yamaguchi S; Tsujimura A; Nonomura N Int J Clin Oncol; 2013 Aug; 18(4):704-10. PubMed ID: 22688162 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of tegafur-uracil (UFT) administration in castration-resistant prostate cancer patients with a history of both alternative antiandrogen therapy and estramustine phosphate sodium hydrate therapy. Hayakawa N; Matsumoto K; Sato A; Sakamoto H; Ezaki T; Maeda T; Ninomiya A; Nakamura S Int Urol Nephrol; 2014 Jun; 46(6):1123-9. PubMed ID: 24356920 [TBL] [Abstract][Full Text] [Related]
12. Final report on low-dose estramustine phosphate (EMP) monotherapy and very low-dose EMP therapy combined with LH-RH agonist for previously untreated advanced prostate cancer. Kitamura T; Suzuki M; Nishimatsu H; Kurosaki T; Enomoto Y; Fukuhara H; Kume H; Takeuchi T; Miao L; Jiangang H; Xiaoqiang L Aktuelle Urol; 2010 Jan; 41 Suppl 1():S34-40. PubMed ID: 20094950 [TBL] [Abstract][Full Text] [Related]
13. Dramatic decline in prostate-specific antigen by withdrawal of estramustine phosphate in hormone refractory prostate cancer. Kobayashi M; Kuramoto H; Ota J; Fujimoto N Int J Urol; 2006 Jul; 13(7):1019-21. PubMed ID: 16882080 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of estramustine phosphate according to risk classification of castration-resistant prostate cancer. Minato A; Fujimoto N; Kubo T; Harada S; Akasaka S; Matsumoto T Med Oncol; 2012 Dec; 29(4):2895-900. PubMed ID: 22323054 [TBL] [Abstract][Full Text] [Related]
15. The Val158Met polymorphism of the catechol-O-methyltransferase gene is associated with the PSA-progression-free survival in prostate cancer patients treated with estramustine phosphate. Suzuki M; Mamun MR; Hara K; Ozeki T; Yamada Y; Kadowaki T; Honda H; Yanagihara Y; Ito YM; Kameyama S; Ohta N; Hosoi T; Arai T; Sawabe M; Takeuchi T; Takahashi S; Kitamura T Eur Urol; 2005 Nov; 48(5):752-9. PubMed ID: 16126332 [TBL] [Abstract][Full Text] [Related]